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Synopsis Venomous organisms used in research were historically chosen based on size and availability. This opportunitydriven strategy created a species bias in which snakes, scorpions, and spiders became the primary subjects of venom
research. Increasing technological advancements have enabled interdisciplinary studies using genomics, transcriptomics,
and proteomics to expand venom investigation to animals that produce small amounts of venom or lack traditional venom
producing organs. One group of non-traditional venomous organisms that have benefitted from the rise of -omic technologies is the Conoideans. The Conoidean superfamily of venomous marine snails includes, the Terebridae, Turridae (s.l),
and Conidae. Conoidea venom is used for both predation and defense, and therefore under strong selection pressures. The
need for conoidean venom peptides to be potent and specific to their molecular targets has made them important tools for
investigating cellular physiology and bioactive compounds that are beneficial to improving human health. A convincing
case for the potential of Conoidean venom is made with the first commercially available conoidean venom peptide drug
Ziconotide (PrialtÕ ), an analgesic derived from Conus magus venom that is used to treat chronic pain in HIV and cancer
patients. Investigation of conoidean venom using -omics technology provides significant insights into predator-driven
diversification in biodiversity and identifies novel compounds for manipulating cellular communication, especially as it
pertains to disease and disorders.

Introduction
Venom is defined as any exogenous substance that is
used to elicit an adverse effect in its target, and as a
result a wide range of organisms from notorious
snakes to lesser known leeches and bees are considered venomous (Fig. 1; Escoubas and King 2009;
Casewell et al. 2013; King 2015; Petras et al. 2015).
Historically, organisms used in venom research were
chosen opportunistically, based on size and ease of
collection, which largely focused on vertebrates, specifically snakes. Two genera of snakes account for
almost 40% of all published venom toxin sequences
in elapid snake venom research (Fry et al. 2008).
Remarkably, one easy to collect genus (Naja) has
been used to identify 40% of all three-finger snake

venom toxins (3FTxs) sequenced. Only three studies
have used harder to milk and less studied, nonfront-fanged snakes to investigate 3FTx bioactivity
(Fry et al. 2003; Pawlak et al. 2006, 2009; King
2015). The venom research strategy of size and accessibility can neglect the ecology, morphology, or
evolutionary relatedness between organisms, resulting
in a diversity of venomous animals, such as invertebrates, being effectively ignored (Modica and
Holford 2010; Puillandre and Holford 2010; von
Reumont et al. 2014b).
Invertebrates are underrepresented in venom research. Spiders, which are the most diverse group
of venomous animals, with about 45,000 species,
make up less than 5% of all venom research studies
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Fig. 1. Biodiversity of venomous taxa. Phylogenetic reconstruction of the tree of life highlighting venomous organisms. Grey bars
represent the clades that include venomous organisms. Highlighted clades represent the traditionally studied venomous taxa (scorpions,
spiders, snakes, and lizards).

(Nentwig 2013). Analogous to the within taxa bias
seen in snakes, of the 17,000 species of scorpions
described, only 50 species have had their venom
investigated (King 2015). It can be argued that the
venom research bias existed largely due to lack of
technological methods for effectively collecting and
characterizing small quantities of venom. The deficiency of invertebrates has led to a dearth of information that has hindered venom research. However,
recent technological advancements in the field of
molecular biology and proteomics has increased the
representation of marine cone snails, sea anemones,
bees, and ants in venom studies (Norton and Olivera
2006; Moran et al. 2008; Barlow et al. 2009; Casewell
et al. 2013; Sanggaard et al. 2014; Zhang et al. 2015).
Extensive research on a broad range of organisms is
imperative in order to effectively derive and test hypotheses about venom as it relates to species

diversification, predator–prey interactions, and to describe the immense biodiversity of animals found on
Earth (Fig. 1).

Rise of -omics
Early research on venom relied heavily on identifying
proteins using Edman degradation and mass spectrometry (MS; Perkins et al. 1993a, 1993b). In conjunction with fractionation, MS allowed for the separation
and identification of individual venom components.
Development of soft ionization methods in the late
1980s, such as electrospray ionization (ESI; Fenn
2003), and matrix-assisted laser desorption (Karas
and Hillenkamp 1988; Tanaka 2003) have revolutionized biological research. In particular, the ability to
identify proteins directly from MS data is a powerful
capability that soon demonstrated to be crucial for
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analyzing venoms. Quickly thereafter, research groups
started to implement MS techniques to characterize
snake venom (Perkins et al. 1993a, 1993b). MS
approaches also enable the identification of isoforms
of venom peptides, slight variations in sequences, and
post translational modifications (Craig et al. 1999;
Escoubas et al. 2008; Safavi-Hemami et al. 2014;
Petras et al. 2015). Recent advancements in MS protocols have produced what are referred to as topdown methods, in which whole intact venom components can be identified (Breuker et al. 2008;
Ueberheide et al. 2009; Anand et al. 2014; Sunagar
et al. 2016). Although groundbreaking, in some organisms a proteome-only MS approach can be problematic. MS requires extraction of venom, which is
impractical for organisms that do not readily store
venom for delivery and other organisms that have
hard-to-access venom delivery systems that prevent
stimulation or extraction (von Reumont et al.
2014a). Additionally, MS methods for determining
primary venom peptide sequences are largely dependent on downstream data analyses of source databases, such as Mascot or Genbank (Perkins et al.
1999; Bhatia et al. 2012). For model organisms with
a rich complement of sequence databases, such as
humans, mice, or drosophila, this is not an issue.
In the case of non-model organisms, the application
of MS methods for primary sequencing is severely
limited by the database used. Non-model systems
generally require de novo sequence assembly and
source databases that are either missing or deficient.
As a result, an integrated strategy, termed venomics
(Calvete et al. 2007; Calvete 2014; Eichberg et al.
2015), in which MS proteomics is combined with
next generation transcriptomic or genomic sequencing and bioinformatic methods is necessary to validate characterization of de novo venom peptides
found in non-model organisms and to paint the
full canvas of venom evolution and variation (Fig.
2; Fry et al. 2013; Sunagar et al. 2016). Using the
multi-omic integrated venomic strategy, venom research has become more accessible to smaller,
harder to collect, and understudied venomous taxa.
The integrated venomic strategy has also broadened
the scientific community engaged in venom research
from traditional chemists and pharmacologists looking for bioactive compounds for drug discovery and
development, to evolutionary biologists looking for
anatomical and molecular characters to understand
venom evolution through various taxa over time
(Duda and Palumbi 1999; Moran et al. 2008;
Favreau and Stöcklin 2009; Elmer et al. 2010; Koh
and Kini 2012; Otvos et al. 2013; Gorson et al.
2015; Jouiaei et al. 2015; Zhang et al. 2015).
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The honey bee, Apis mellifera, was the first venomous organism to have a fully sequenced genome using
Sanger sequencing (Weinstock et al. 2006). Since then,
the development of next generation sequencing (NGS)
high throughput techniques has allowed rapid sequencing of other venomous organisms. The genomes of
tarantula Acanthoscurria geniculate (Sanggaard et al.
2014), scorpion Mesobuthus martensii (Cao et al.
2013), velvet spider Stegodyphus mimosarum
(Sanggaard et al. 2014), fire ant Soenopsis invicta
(Wurm et al. 2011), and king cobra Ophiophagus
hannah (Vonk et al. 2013) have all been sequenced
using NGS technologies. With multiple platforms available, such as Illumina (Illumina, Inc., San Diego,
California), 454 (Roche Applied Science, Penzberg,
Germany), SOLiD (ThermoFisher Scientific, Waltham,
Massachusetts), and Ion Torrent (ThermoFisher
Scientific, Waltham, Massachusetts), genome sequencing of venomous organisms is becoming both accessible and affordable. However, genomics alone does not
provide enough information for determining the exact
mode and tempo of gene expression and does not give
significant insight into differential gene expression
within various tissue types (Sunagar et al. 2016).
While genomics is the study of the complete DNA
composition of an organism, venom gland transcriptomics is the sequencing of mRNA specific to the
venom gland or secretory tissue of a venomous organism and therefore a glimpse at the specific venom
cocktail being used at the time by the animal
(Durban et al. 2011; Dutertre et al. 2014; Gorson
et al. 2015; Sunagar et al. 2016). Both transcriptomics and genomics enable the identification of certain domains of a venom protein, such as the signal
and pre-pro regions that are rarely identified on the
proteomic level as they are cleaved off after translation (Duda and Palumbi 1999; Espiritu et al. 2001;
Kaas et al. 2010; Robinson and Norton 2014;
Sunagar et al. 2016). Employing an integrated
venomic strategy has enabled researchers to resolve
previously unanswerable questions, such as identifying a correlation between varying venom compositions and differences in ecological and environmental
factors. Several studies employing a combined genomics and transcriptomics approach have looked at
venom variation between different developmental
stages in snakes (Durban et al. 2011; Durban et al.
2013; Gibbs et al. 2013). Specifically, proteomics and
transcriptomics were used to show venom variation
in various populations of the Southern Pacific
Rattlesnake, Crotalus oreganus helleri in the United
States (Sunagar et al. 2014). Lectin -chains, which
are generally undergoing positive selection, were
found to be evolving under negative selection in
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Fig. 2. Venomics: an integrated NGS and proteomic strategy. An integrated multi -omics approach using genomic, transcriptomic,
bioinformatic, and proteomic protocols to identify venom proteins and peptides. Application of a combined -omics strategy validates de
novo venom peptide/protein identification and provides robust data to test hypotheses related to venom evolution and ecology. The
sequences shown at the bottom are an example of a validated peptide database obtained from NGS and proteomics.

the C. oreganus helleri rattlesnake population found
on Catalina Island (in the Pacific Ocean; Sunagar et
al. 2014). The integrated venomics approach used in
this study revealed that there can be different evolutionary selection pressures acting on different venom
classes depending on the population site. In another
study that used an integrative venomics approach, it
was found that there were significant differences in
the mature peptides being produced in different
samples of venom from Conus consors (Biass et al.
2015). Proteomics and transcriptomics were used to
analyze C. consors venom at three different stages:
venom milked from the snail, venom extracted
from the venom gland, and venom expressed in

the transcriptome, effectively tracing the venom production and delivery process from the venom glad
tissue to the point of venom envenomation of the
prey. The surprising result was that the cocktail of
venom peptides identified in the transcriptome, in
the venom produced within the venom gland, and
in the venom injected into the prey were not heavily
correlated. Each venom compartment was distinctive
in terms of peptide and protein content. This study
emphasizes the complexity of the venom mechanism
of Conodiean snails and indicates what is being secreted in the venom is not necessarily the same as
what is being produced in the gland (Biass et al.
2015).
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Advances in -omic technologies have increased the
breadth of research being done on all organisms and
have advanced research of non-model organisms.

Characterizing Conoidean Venom
Evolution and Variation
The technological -omics advancements removed the
barrier requiring large amounts of crude venom extracts and smaller-sized taxa such as centipedes, certain sea anemones, ants, and small scorpions have
become the focal point of an ever increasing
number of venom studies (Putnam et al. 2007;
Moran et al. 2008; Calvete et al. 2009; Cao et al.
2013; Sanggaard et al. 2014; Xu et al. 2014). One
non-model organism that has received a lot of attention using venomic technologies is the venomous
marine snails in the Conoidean superfamily.
Conoidean snails are slow moving predators and
therefore rely heavily on the efficacy of their venom
(Azam et al. 2005; Yao et al. 2008; Kendel et al.
2013; King 2015). The dependence on venom for
prey capture has led conoidean venom peptides to
achieve incredible molecular specificity (Olivera
2002; Olivera et al. 2014). Conoideans subdue
their prey using a venom apparatus made up of a
proboscis, radular tooth, a radular sac, venom gland,
and venom bulb (Fig. 3(A); Taylor 1990; Kantor et
al. 2000; Modica and Holford 2010; Kantor and
Puillandre 2012). Cone snails (Conus) are the most
studied in the Conoidea (Puillandre et al. 2014;
Puillandre et al. 2015); however, Conus comprises
only 5% of the biodiverse group of venomous
marine snails (Olivera et al. 1999; Holford et al.
2009; King 2015). Other non-Conus Conoideans,
such as the Turridae (s.l.) family, which has more
recently been divided into seven family groups
(Tucker and Tenorio 2009; Bouchet et al. 2011),
and the Terebridae family, also produce venom
(Heralde et al. 2008; Aguilar et al. 2009; Gonzales
and Saloma 2014; Gorson et al. 2015; Moon et al.
2016). Cone snails and terebrids dwell in shallowwater tropical marine habitats, while the majority of
turrids can be found at greater depths (4200m;
Taylor 1977). Terebrids and turrids (some less
than 3 mm in length) have incredibly small venom
ducts, producing limited amounts of venom, which
initially inhibited their characterization. Using an
integrated venomics strategy, venom research of terebrids and turrids has become more feasible
(Castelin et al. 2012; Kendel et al. 2013; Gonzales
and Saloma 2014; Gorson et al. 2015; Moon et al.
2016).

Fig. 3. Conoidean venom characterization. (A) A generic representation of the Conoidean venom apparatus, which includes: a
venom bulb that is contracted to push the venom through the
venom gland, where the venom is being produced, a radular sac
that contains hollowed teeth (harpoons) that are used to inject
venom into the prey, and a proboscis that extends several times
beyond the snails body size to deliver venom-filled radula to a
prey target. Scissors shown represent the dissection of the
venom duct for downstream analysis by transcriptomic, genomic
or proteomic methods. (B) Identification of Conus venom peptide
superfamilies and cysteine frameworks. (C) Conoidean venom
peptides selected for bioactivity characterization. MVIIA is a
peptide from Conus magus venom that produced the ziconotide
(PrialtÕ ) drug that is commercially available. MVIIA is in the O1
conotoxin gene superfamily and has a VI/VII cysteine framework.
Tv1 is a peptide from Terebra variagata that has a cysteine pattern
similar to the M-superfamily in cone snails and has a III cysteine
framework, but has a peptide fold of antiparallel beta hairpins
that is unique to known venom peptides. Tv1 and MVIIA are very
distinct peptides illustrating the disparate complexity of
Conoidean venom peptides.

Conoidean venoms are a complex mixture of
small molecules, peptides and proteins (Norton and
Olivera 2006; Gonzales and Saloma 2014; Gorson et
al. 2015; Neves et al. 2015). Each Conoidean venom
consists of4100 different peptides which contain a
signal sequence, followed by a pro region, and a
mature peptide at the C-terminus (Olivera et al.
1999; Lavergne et al. 2015). As cone snails are well
studied, 3000 different peptides (conotoxins) have
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been identified from Conus venoms since the 1970s
(Conoserver.org). The majority of conotoxins have
been classified into venom gene superfamilies by examining the sequence identity of the signal sequence
(Jacob and McDougal 2010; Robinson et al. 2014;
Robinson and Norton 2014). A similar process is
being used to characterize turrid and terebrid
venom peptide superfamilies (Fig. 3(B); Heralde et
al. 2008; Gonzales and Saloma 2014; Gorson et al.
2015). Different venom peptide superfamilies generally have distinct physiological targets and high specificity for those targets (Olivera et al. 1999). While
there are similarities between the venoms of Conus,
inter- and intraspecific variation exists, such as differences in the proportions of cysteine frameworks or
venom gene superfamilies (Duda and Palumbi 1999;
Olivera et al. 1999; Jakubowski et al. 2005; Romeo et
al. 2008; Abdel-Rahman et al. 2011). Due to the high
rates of non-synonymous mutations and the early
divergence of Conoidean families, the venoms of terebrids and turrids (s.l.) vary significantly from the
venoms of cone snails (Powell 1966; Duda and
Palumbi 1999; Puillandre and Holford 2010;
Gorson et al. 2015). The disparity in Conus and terebrid venom was recently revealed by looking at the
variation in venom peptide superfamilies between
Triplostephanus anilis and Terebra subulata (Gorson
et al. 2015). Fourteen terebrid venom gene superfamilies were identified in the two terebrid species
(TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK,
TL, and TM). Of the fourteen terebrid superfamilies
described, only one, TM, is homologous to a superfamily found in Conus marmoreus (H superfamily;
Robinson and Norton 2014). The divergence of
Conus and terebrid venom gene superfamilies suggests that terebrid venom peptides will have different
structural features and physiological targets from
Conus, thereby increasing the pool of bioactive compounds that can be explored for discovery of novel
therapeutic drugs. Conoidean venoms are exceedingly effective candidates for drug discovery as they
are: (1) rapid acting, (2) highly selective, and (3)
very potent (Fig. 3(C)).

Potential of Conoidean Venom to
Increase Drug Discovery and
Development
Many bioactive peptides have evolved as a means of
predation or defense, especially in venomous animals
(Olivera et al. 1985; Gray et al. 1988; Olivera et al.
1999; Dutertre et al. 2014). The wide variety of biologically active venom peptides are a promising resource for drug discovery (Lewis and Garcia 2003;
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Favreau and Stöcklin 2009; Twede et al. 2009; Koh
and Kini 2012; King 2015; Ortiz et al. 2015). The
constant selective pressures acting on venom, due
to the effects of the predator–prey arms race (Van
Valen 1973; Dawkins and Krebs 1979; Casewell et al.
2013; Holding et al. 2016), enabled venom peptides
to develop features to increase stability and prey molecular target affinity. Venom peptides tend to interfere with transmissions of ions in and out of cells,
suggesting they would be effective tools for manipulating ion channel driven cell disorders such as pain
or cancer (Miljanich 2004; Vetter and Lewis 2012;
Lang et al. 2014). These properties make venom peptides more appealing than artificially or chemically
conceived peptide-like compounds for which bioactivity is not guaranteed (Uhlig et al. 2014).
The past two and a half decades have seen an increase in the number of projects that are taking advantage of the Earth’s amazingly biodiverse group of
venomous organisms to develop novel drugs, to create
tools for diagnosing human diseases, and to create
probes to help advance the study of molecular receptors and physiological pathways (Nisani et al. 2007;
King 2011; Diochot et al. 2012; Casewell et al. 2013).
As reptiles were the most accessible venomous organisms for quite some time, the majority of approved
venom drugs were discovered from snake venom.
Specifically, snake venom proteins targeting thrombin,
integrin, and fibrinogen receptors were discovered
(King 2011; Koh and Kini 2012). CaptoprilÕ , an angiotensin-converting enzyme (ACE) inhibitor synthesized to mimic a venom peptide from Brazilian
lancehead snakes, is a breakthrough drug that validates venom-based drug discovery research
(Cushman and Ondetti 1991). The venomic strategy
has made it more affordable and practical to examine
non-model venomous organisms for peptide or protein components that can lead to new therapeutics.
Investigating more venomous organisms will greatly
increase the amount of compounds available for
drug discovery and development (Puillandre and
Holford 2010; Casewell et al. 2013; King 2015).
The41 million estimated venom peptides expressed in conoidean venom are an immense resource for discovering novel compounds for
therapeutic drug development. The majority of conoidean venom peptides are disulfide-rich molecules
that have been shown to manipulate voltage and
ligand gated potassium (Kþ), calcium (Ca2þ), and
sodium (Naþ) channels, as well as nicotinic acetylcholine receptors, and noradrenaline transporters
(Olivera 2002; Terlau and Olivera 2004; Becker and
Terlau 2008; Fig. 4). As mentioned previously, ion
channels and receptors are the molecular targets for
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Fig. 4. Snail venom peptides to drugs. Conoidean venom peptides under drug development.

cancer, pain, and other debilitating human disorders
(Wood et al. 2004; Veiseh et al. 2007; Gkika and
Prevarskaya 2011; Dave and Lahiry 2012; Lang et
al. 2014). Ziconotide (PrialtÕ ), a peptide from the
venom of Conus magus, was approved for commercial use by the Food and Drug Administration in
2004 and is the first non-opiod analgesic (Olivera
2000; Miljanich 2004; Schmidtko et al. 2010).
Similar to MVIIA, CVID, MrIA, Vc1.1, RgIA,
Contulakin-G, and Conantokin-T are peptides synthesized from the natural secretions of Conus that are
currently undergoing clinical trials to determine of
their potential as pain therapeutics (Fig. 4; Malmberg
et al. 2003; Miljanich 2004; Armishaw and Alewood
2005; Vincler et al. 2006; Han et al. 2008; McIntosh
et al. 2009). Although most Conus peptides in pharmaceutical development are being used as analgesics,
PVIIA shows promise as a therapy for myocardial
infarction, and Conantokin-G for epilepsy (Fig. 4;
Koch et al. 2004; Armishaw and Alewood 2005;
Twede et al. 2009).

venomics strategy has enabled a broader range of
venomous organisms, many of which are nonmodel organisms, difficult to acquire, and contain
limited amounts of venom, to be examined and ultimately contribute to the understanding of venom
evolution in biodiversity. Without the vast technological molecular improvements in the last decade,
studies would most likely still revolve around
snakes, spiders, and scorpions. The increasing
amount of venom peptides identified from
Conoideans that are now in clinical trials, demonstrates the importance of expanding the diversity of
venomous species examined (Fig. 4). As -omics technology continues to improve, it will be easier and
cheaper to add more species to the pool of venomous organisms under investigation, enabling researchers to resolve questions about venom
convergence across the animal kingdom and increase
the quantity of peptides available for drug discovery
and development for the benefit of human health.
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V, Quinoñez J, Moy P, Chait BT, Poget SF, Holford M.
2014. Sample limited characterization of a novel disulfiderich venom peptide toxin from terebrid marine snail
Terebra variegata. PLoS One 9:e94122.
Armishaw CJ, Alewood PF. 2005. Conotoxins as research
tools and drug leads. Curr Prote Pept Sci 6:221–40.
Azam L, Dowell C, Watkins M, Stitzel JA, Olivera BM,
McIntosh JM. 2005. Alpha-conotoxin BuIA, a novel peptide
from Conus bullatus, distinguishes among neuronal nicotinic acetylcholine receptors. J Biol Chem 280:80–7.
Barlow A, Pook CE, Harrison RA, Wüster W. 2009.
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